Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice Laura Detti, M.D., Rebecca A. Uhlmann,

Slides:

Advertisements

Similar presentations

Effect of detorsion alone and in combination with enoxaparin therapy on ovarian reserve and serum antimüllerian hormone levels in a rat ovarian torsion.

Advertisements

Mouse strain and quality control testing: improved sensitivity of the mouse embryo assay with embryos from outbred mice Zaraq Khan, M.B.B.S., Heather S.

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States David B. Seifer, M.D., Valerie.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Age at menarche: a predictor of diminished ovarian function?

Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.

Keri Greenseid, M. D. , Sangita Jindal, Ph. D. , Athena Zapantis, B. S

Daily physical activity and hot flashes in the Study of Women's Health Across the Nation (SWAN) Flashes Study Carolyn Gibson, M.P.H., M.S., Karen Matthews,

Karl R. Hansen, M. D. , Ph. D. , George M. Hodnett, M. D

Infertility evaluation and treatment among women in the United States

Michael M. Alper, M.D. Fertility and Sterility

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Ovarian pregnancy after in vitro fertilization

Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause Linlin Cui, M.D., Ph.D., Yingying.

Growth rates of ovarian follicles during natural menstrual cycles, oral contraception cycles, and ovarian stimulation cycles Angela R. Baerwald, Ph.D.,

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women Ellen W. Freeman, Ph.D.,

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Simone L. Broer, B.Sc., Ben Willem J.

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH) P. Barriere, T. Freour, D. Masson,

Angela R. Baerwald, Ph. D. , Olufemi A. Olatunbosun, M. D. , Roger A

Modification of the Beckman-Coulter second-generation enzyme-linked immunosorbent assay protocol improves the reliability of serum antimüllerian hormone.

Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: a phase II, randomized, dose-finding study Donald Tredway, M.D., Ph.D.,

Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling.

Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes Aaron.

Rahi Victory, M. D. , F. R. C. S. C. , Ghassan M. Saed, Ph. D

Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial Robert Boostanfar, M.D.,

A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization Laura Detti, M.D., Daniel B. Williams, M.D., Jared.

Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis Laura P. Smith, M.D.,

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Does stimulation with human gonadotropins and gonadotropin-releasing hormone agonist enhance and accelerate the developmental capacity of oocytes in human.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Robotic-assisted laparoscopic ovarian tissue transplantation

Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis Reshef Tal,

Is anti-Müllerian hormone a marker of acute cyclophosphamide-induced ovarian follicular destruction in mice pretreated with cetrorelix? Hyacinth N. Browne,

Ovarian hyperstimulation secondary to ectopic secretion of follicle-stimulating hormone. Literature review prompted by a case Jorge Burgos, M.D., Patricia.

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Laura Detti, M. D. , Rebecca A. Uhlmann, M. S. , Nicole M. Fletcher, B

Endometrial morphology and modulation of hormone receptors during ovarian stimulation for assisted reproductive technology cycles Laura Detti, M.D.,

Francesco Plotti, M. D. , Alessandra Di Giovanni, M. D

Xenotransplantation of cryopreserved ovarian tissue from patients with ovarian tumors into SCID mice—no evidence of malignant cell contamination Laura.

Simple tools for assessment of ovarian reserve (OR): individual ovarian dimensions are reliable predictors of OR Stacea Bowen, M.D., John Norian, M.D.,

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Effects of hyperglycemia on the differential expression of insulin and insulin-like growth factor-I receptors in human normal peritoneal and adhesion.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins:

Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence

Sedigheh Borna, M.D., Azita Nasery, M.D. Fertility and Sterility

Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.

Genetic evaluation procedures at sperm banks in the United States

A woman with premature ovarian failure induced by Tripterygium wilfordii Hook.f. gives birth to a healthy child Xin Chen, M.D., M.Sc., Shi-ling Chen,

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D

Bárbara Oriol, M. D. , Ana Barrio, M. D. , Alberto Pacheco, Ph. D

Early menopause in mothers of children with Down syndrome?

Ovarian follicular volume and follicular surface area are better indicators of follicular growth and maturation, respectively, than is follicular diameter

Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient’s body mass index and the number of larger follicles

Lauren F. Damle, M. D. , Veronica Gomez-Lobo, M. D. , Amy R. Andrus, M

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.

Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization Rongrong Tan, M.M.Sc., Danhua Pu,

Presentation transcript:

Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice Laura Detti, M.D., Rebecca A. Uhlmann, M.S., Jie Zhang, M.D., Michael P. Diamond, M.D., Ghassan M. Saed, Ph.D., Nicole M. Fletcher, Ph.D., Meifen Lu, B.S., Lucy J. Williams, E.L.D. Fertility and Sterility Volume 101, Issue 4, Pages 1157-1164.e1 (April 2014) DOI: 10.1016/j.fertnstert.2013.12.028 Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Study design flowchart. Fertility and Sterility 2014 101, 1157-1164.e1DOI: (10.1016/j.fertnstert.2013.12.028) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions

Figure 2 (A and B) Follicles in a prepubertal ovary stained with hematoxylin and eosin (H&E) and TUNEL, respectively. (C) Adult femur stained with H&E. (D) Detail of the growth plate section stained with H&E (with computerized measurements). (E) Detail of the growth plate section stained with TUNEL. Fertility and Sterility 2014 101, 1157-1164.e1DOI: (10.1016/j.fertnstert.2013.12.028) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Antimüllerian hormone (AMH) and follicle-stimulating hormone (FSH) serum levels and total follicle count at ages 56 days (A) and 92 days (B). *P<.05. Fertility and Sterility 2014 101, 1157-1164.e1DOI: (10.1016/j.fertnstert.2013.12.028) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 1 Femur growth plate average thickness across the treatment groups at age 20 and 92 days. Fertility and Sterility 2014 101, 1157-1164.e1DOI: (10.1016/j.fertnstert.2013.12.028) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions